药明康德 (603259)

WuXi AppTec Co., Ltd.

ASH

Tags

300ESG Index300 Non-Cyclical IndexContract Research Organization (CXO)MSCI China A 50 IndexMSCI Component StocksSSE 180 IndexSSE 50 IndexSpecial Purpose LoansChina A80 IndexCSI 100 IndexCSI A100 IndexCSI A50 IndexCSI Share Buyback IndexCSI Leading Enterprises IndexInnovative DrugsNorthbound Heavy PositionsPharmaceuticals and HealthcareContains H-SharesGuozheng Growth IndexGene ConceptFund Heavy PositionsForeign Capital BackgroundLarge Cap GrowthLarge Cap StocksPlanned Reduction of HoldingsEmerging Markets IndexCSI 300 IndexOverseas BusinessConsumption 100 IndexResearch and Experimental DevelopmentHigh-Performing StocksMargin Trading and Securities LendingIndustry LeadersTongdaxin 88Galaxy 99 IndexYangtze River DeltaNon-Cyclical StocksHigh Accounts Receivable医药生物Medical Services

K-Line Chart

No K-line data available

Company NameWuxi AppTec Co., Ltd.
Listing Date2018-05-08
Issue Price21.6RMB
Registered Capital288799.258210k RMB
Legal RepresentativeGe Li
Registered AddressNo. 5 Bridge, Mashan, Binhu District, Wuxi City, Jiangsu Province
IndustryMedical Services
Main BusinessComprehensive, integrated platform services for the discovery, research, development, and production of small-molecule chemical drugs, providing global pharmaceutical companies with R&D, production, and supporting services for various new drugs in the form of a full-industry-chain platform; in addition, the issuer also provides medical device testing and overseas precision medicine R&D and production services.
Company ProfileFounded in December 2000, WuXi AppTec is a global leading open-access capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries. As a research-driven, customer-focused company, WuXi AppTec provides a comprehensive portfolio of laboratory research, development, and manufacturing services to global pharmaceutical, biotechnology, and medical device companies, covering the entire process from drug discovery to commercialization. WuXi AppTec's services are designed to help global clients shorten the R&D cycle and reduce costs for drugs and medical devices through cost-effective and efficient R&D services.

Stock Details

1. Key Indicators

  • Total Shares(W): 298375.72
  • Circulating A-Shares(W): 247328.02
  • Earnings Per Share(RMB): 4.2500
  • Net Assets Per Share(RMB): 23.9230
  • Operating Revenue(W RMB): 3285671.65
  • Total Profit(W RMB): 1503706.84
  • **Net Profit Attributable to Parent(W RMB) **: 1207551.30
  • Net Profit Growth Rate(%): 84.84
  • Weighted Return on Equity(%): 19.2600
  • Operating Cash Flow Per Share(RMB): 3.8480
  • Undistributed Profit Per Share(RMB): 13.1940
  • Capital Reserve Per Share(RMB): 10.7013

2. Main Business

The main business covers:

  • Integrated platform services for the discovery, research, development, and production of small molecule chemical drugs

3. Company Basic Information

  • Company Name: Wuxi AppTec Co., Ltd.
  • Listing Date: 2018-05-08
  • Industry: Medicine and Healthcare - Medical Services (Tongdaxin Research Industry)
  • Address: Registered Address: No. 5 Bridge, Mashan, Binhu District, Wuxi City, Jiangsu Province; Office Address: No. 288 Fute Middle Road, Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai
  • Website: https://www.wuxiapptec.com.cn/
  • Company Profile: The issuer was established through the overall change of Wuxi AppTec Limited. On February 16, 2017, approved by the board of directors of Wuxi AppTec Limited, all the original shareholders of Wuxi AppTec Limited acted as promoters, converting the audited net assets of Wuxi AppTec Limited as of January 31, 2017, amounting to RMB 3,249,774,976.95, into the share capital of the joint-stock company of RMB 937,787,000, with the remaining portion included in the capital reserve. Wuxi AppTec Limited was wholly transformed into a joint-stock company, and its name was changed to Wuxi AppTec Co., Ltd. On February 17, 2017, Deloitte Touche Tohmatsu verified the capital contribution for the issuer's transformation into a joint-stock company and issued the "Capital Verification Report" (De Shi Bao (Verification) Zi (17) No. 00090). On March 1, 2017, the issuer completed the change registration at the Wuxi Administration for Industry and Commerce and obtained the "Business License" with the unified social credit code 91320200724183068U.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hong Kong Securities Clearing Company Ltd. Northbound Funds 24893.05 10.06
2 G&C VI Limited Corporate Entity 14301.58 5.78
3 G&C IV Hong Kong Limited Corporate Entity 10462.61 4.23
4 Beijing Zhongmin Yinfu Investment Management Co., Ltd. - Jiaxing Yuxiang Investment Partnership (Limited Partnership) Asset Management Plan 8707.46 3.52
5 G&C V Limited Corporate Entity 7310.58 2.96
6 SSE 50 ETF Fund 4778.07 1.93
7 Huatai-PineBridge CSI 300 ETF Fund 4268.15 1.73
8 G&C VII Limited Corporate Entity 3785.33 1.53
9 Shanghai Houshen Investment Center (Limited Partnership) Corporate Entity 3488.20 1.41
10 Huabao CSI Medical ETF Fund 3436.70 1.39

5. Concept Sectors

  • H-Share
  • Tongdaxin 88
  • Gene Concept
  • CXO Concept
  • Innovative Drug
  • Margin Trading
  • Foreign Background
  • Large Cap Stock
  • High-Performance Stock
  • Heavily Held by Funds
  • Industry Leader
  • High Beta
  • Hundred-Yuan Stock
  • MSCI Constituent
  • Planned Reduction
  • Overseas Business
  • Heavily Held by Northbound Funds
  • Non-Cyclical Stock
  • High Receivables
  • Special Loans
  • SSE 50
  • CSI 100
  • SSE 180
  • Galaxy 99
  • Large Cap Growth
  • Consumption 100
  • SZSE Growth
  • CSI 300
  • China A80
  • 300 Non-Cyclical
  • CSI Leaders
  • 300 ESG
  • MSCI China A50
  • SME-ChiNext Index
  • Yangtze River Delta
  • CSI Buyback
  • CSI A50
  • CSI A100

Remarks

  • Data update date: 2025-11-04
  • Data source: Public market information